Pfizer Inc. (NYSE:PFE) Shares Sold by Westbourne Investment Advisors Inc.

Westbourne Investment Advisors Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 22.0% during the second quarter, Holdings Channel reports. The firm owned 19,844 shares of the biopharmaceutical company’s stock after selling 5,600 shares during the quarter. Westbourne Investment Advisors Inc.’s holdings in Pfizer were worth $860,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PFE. Fisher Asset Management LLC increased its position in shares of Pfizer by 3.3% during the fourth quarter. Fisher Asset Management LLC now owns 41,830,709 shares of the biopharmaceutical company’s stock worth $1,825,910,000 after acquiring an additional 1,352,978 shares during the period. California Public Employees Retirement System increased its position in shares of Pfizer by 14.0% during the fourth quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after acquiring an additional 2,504,336 shares during the period. APG Asset Management N.V. increased its position in shares of Pfizer by 1.4% during the fourth quarter. APG Asset Management N.V. now owns 16,360,380 shares of the biopharmaceutical company’s stock worth $624,704,000 after acquiring an additional 228,300 shares during the period. Rhumbline Advisers increased its position in shares of Pfizer by 1.2% during the fourth quarter. Rhumbline Advisers now owns 9,449,884 shares of the biopharmaceutical company’s stock worth $412,487,000 after acquiring an additional 113,506 shares during the period. Finally, TD Asset Management Inc. increased its position in shares of Pfizer by 1.5% during the fourth quarter. TD Asset Management Inc. now owns 8,723,552 shares of the biopharmaceutical company’s stock worth $380,783,000 after acquiring an additional 129,557 shares during the period. Institutional investors own 71.81% of the company’s stock.

In other Pfizer news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

A number of analysts have recently weighed in on the company. Barclays reaffirmed a “hold” rating and set a $41.00 price objective on shares of Pfizer in a research report on Thursday, May 9th. Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research report on Monday, June 17th. Credit Suisse Group started coverage on Pfizer in a report on Monday, July 15th. They issued a “hold” rating and a $47.00 target price on the stock. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Finally, UBS Group reissued a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a report on Monday. Fifteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $46.24.

Shares of PFE stock traded down $0.20 during mid-day trading on Tuesday, hitting $36.76. 583,563 shares of the stock were exchanged, compared to its average volume of 28,709,808. The firm’s fifty day moving average price is $42.54. The company has a market capitalization of $211.28 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 3.03 and a beta of 0.63. Pfizer Inc. has a 12-month low of $36.41 and a 12-month high of $46.47. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The business’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.77 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.8 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.92%. The ex-dividend date is Thursday, August 1st. Pfizer’s payout ratio is 48.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Cost of Equity For A Business, Investors

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.